Troxerutin improves diabetic cognitive dysfunction by inhibiting mitochondrial fission mediated by transient receptor potential melastatin 7/calcineurin/dynamin-related protein 1ser637

Figure 12  Troxrutin improved diabetic cognitive dysfunction by inhibiting the transient receptor potential melastatin 7/calcineurin/p-dynamin-related protein 1^ser637 pathway. A: The normalized mRNA expression of transient receptor potential melastatin 7 (TRPM7) and calcineurin (CaN); B: The relative protein expression of TRPM7, CaN, and p-Drp1^ser637; C: Immunofluorescent staining of TRPM7, CaN, and p-Drp1^ser637. ^aP < 0.05, compared with control group; ^bP < 0.05, compared with diabetes group; ^cP < 0.05, compared with diabetes + troxerutin group. Data presented as mean ± SEM. TRPM7: Transient receptor potential melastatin 7; Drp1: Dynamin-related protein 1; CaN: Calcineurin; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; DAPI: 4’,6-diamidino-2-phenylindole; dm: Control group; dm-T: Control + troxerutin group; db: Diabetes group; db-T: Diabetes + troxerutin group; db-T-B: Diabetes + troxerutin + bradykinin group.